BFRI BIOFRONTERA INC

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Biofrontera Inc. to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Woburn, MA, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc., (Nasdaq:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025.

Company Webcast

The webcast presentation will take place at 1:15 p.m. ET on Tuesday, September 30, 2025. The webcast can be accessed by visiting the conference home page at or directly at . The webcast will also be available for replay following the event.

1x1 Meetings

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at or register for the event at .

About Biofrontera Inc.

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions with a focus on PDT. The Company commercializes the drug-device combination Ameluz ® with the RhodoLED ® lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. The Company performs clinical trials to extend the use of the products to treat non-melanoma skin cancers and moderate to severe acne. For more information, visit and follow Biofrontera on and .

Investor Relations Contact

Ben Shamsian

Lytham Partners

646-829-9701



EN
26/09/2025

Underlying

BFRIBIOFRONTERA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BIOFRONTERA INC

 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA appro...

Biofrontera Inc. Completes Transfer of Ameluz® and RhodoLED® FDA approval and Associated Intellectual Property Portfolio • Ameluz® and RhodoLED® New Drug Application (NDA) and Investigational New Drug Application (IND) have successfully been transferred to Biofrontera Inc.• Assignment to Biofrontera Inc. of 11 granted US patents, 10 pending US patent applications and various trademarks associated with Ameluz® and the RhodoLED® Lamp Series has been applied for registration with the relevant authorities, including the US Patent Office (USPTO)• In addition, 19 international patent applications...

December 18, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of...

Last Patient Completes Biofrontera’s Phase 1 Pharmacokinetics Study of Ameluz® for Treatment of Actinic Keratoses on the Trunk and Extremities Phase 1 Maximal-use Phase 1 study evaluated pharmacokinetic (PK) profile following application of 3 tubes of Ameluz® over treatment area of 240 cm2Completion of this study marks a key milestone towards a planned summer 2026 FDA submission for FDA approval for the use of Ameluz® on all non-face and scalp areas WOBURN, Mass., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical compa...

December 4, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Announces Filing of Supplemental New Drug Application...

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT sNDA for treatment of sBCC with Ameluz®-PDT submitted to U.S. Food and Drug Administration (FDA) on November 28, 2025First Phase 3 PDT study in patients with sBCC in the United States submitted to FDAPrimary and key secondary endpoints met with high statistical significance (p

December 2, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Prov...

Biofrontera Inc. Reports Third Quarter 2025 Financial Results and Provides a Business Update Conference call will be held today, Thursday, November 13 at 10:00 am ET Woburn, MA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, today reported financial results for the three and nine months ended September 30, 2025 and provided a business update. Financial highlights Revenues for the first nine months of 2025 were stable with $24...

November 13, 2025 1 EN
 PRESS RELEASE
Free
BFRI BIOFRONTERA INC

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream t...

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expected to fund Biofrontera to profitability.Proceeds will support the growth of Biofrontera’s commercial photodynamic therapy (PDT) platform, and expansion of Ameluz® into additional indications. WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) --...

November 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch